Published in Mol Ther on April 03, 2007
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A (2007) 2.30
A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Development of universal antidotes to control aptamer activity. Nat Med (2009) 1.93
Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
New generation humanized mice for virus research: comparative aspects and future prospects. Virology (2013) 1.38
A boost for the emerging field of RNA nanotechnology. ACS Nano (2011) 1.17
Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. J Virol (2012) 1.12
Hematopoietic stem cell engineering at a crossroads. Blood (2011) 1.10
Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol Ther (2010) 1.03
Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther (2009) 1.03
Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One (2012) 1.01
Novel approaches to inhibit HIV entry. Viruses (2012) 1.00
Stem cell-based anti-HIV gene therapy. Virology (2011) 0.94
Novel HIV-1 therapeutics through targeting altered host cell pathways. Expert Opin Biol Ther (2009) 0.94
Preclinical in vivo evaluation of the safety of a multi-shRNA-based gene therapy against HIV-1. Mol Ther Nucleic Acids (2013) 0.93
Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization. J Acquir Immune Defic Syndr (2009) 0.91
Aptamers in immunotherapy. Hum Gene Ther (2008) 0.89
Stable gene transfer of CCR5 and CXCR4 siRNAs by sleeping beauty transposon system to confer HIV-1 resistance. AIDS Res Ther (2008) 0.88
Expression strategies for short hairpin RNA interference triggers. Hum Gene Ther (2008) 0.88
Recent developments in human immunodeficiency virus-1 latency research. J Gen Virol (2013) 0.87
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther (2010) 0.87
Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors. Acta Naturae (2013) 0.83
Human embryonic stem cell (hES) derived dendritic cells are functionally normal and are susceptible to HIV-1 infection. AIDS Res Ther (2008) 0.83
RNA-based gene therapy for the treatment and prevention of HIV: from bench to bedside. Yale J Biol Med (2011) 0.82
Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt. Stem Cells Int (2011) 0.82
CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape. Viruses (2015) 0.81
Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses (2013) 0.80
siRNA-based topical microbicides targeting sexually transmitted infections. Curr Opin Mol Ther (2010) 0.79
Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene. Hum Gene Ther (2015) 0.79
Bone Marrow Gene Therapy for HIV/AIDS. Viruses (2015) 0.79
Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors. Biology (Basel) (2012) 0.78
Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. Adv Drug Deliv Rev (2016) 0.78
Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs. Antimicrob Agents Chemother (2011) 0.77
Stem cell-based therapies for HIV/AIDS. Adv Drug Deliv Rev (2016) 0.77
Ribonucleic acid interference induced gene knockdown. J Indian Soc Periodontol (2013) 0.75
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol (2002) 8.31
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem (2008) 2.17
HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model. Retrovirology (2006) 2.17
Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant (2003) 2.03
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res (2009) 2.02
An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med (2011) 1.93
RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol (2007) 1.91
Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther (2002) 1.85
Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther (2003) 1.82
Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice. Virology (2008) 1.81
Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing. EMBO J (2006) 1.80
Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice. Virology (2007) 1.78
Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood (2004) 1.74
Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant (2011) 1.55
A mouse model for human norovirus. MBio (2013) 1.51
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One (2010) 1.48
Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther (2003) 1.46
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood (2004) 1.44
Identification of novel influenza A virus proteins translated from PA mRNA. J Virol (2012) 1.42
Absence of functional EpoR expression in human tumor cell lines. Blood (2010) 1.41
Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther (2007) 1.40
A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A (2002) 1.39
Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant (2009) 1.35
Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol (2004) 1.34
Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr (2013) 1.34
RNAi mechanisms and applications. Biotechniques (2008) 1.30
Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol (2010) 1.28
Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses (2003) 1.23
Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther (2005) 1.21
Derivation of normal macrophages from human embryonic stem (hES) cells for applications in HIV gene therapy. Retrovirology (2006) 1.21
Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides (2003) 1.20
A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One (2011) 1.19
Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology (2009) 1.16
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther (2011) 1.16
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res (2011) 1.15
Hematopoietic cell transplantation with cord blood for cure of HIV infections. Biol Blood Marrow Transplant (2012) 1.13
Brief report: phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells (2011) 1.13
Biological and health effects of exposure to kerosene-based jet fuels and performance additives. J Toxicol Environ Health B Crit Rev (2003) 1.12
siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res (2003) 1.12
Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology (2012) 1.12
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem (2009) 1.11
CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology (2005) 1.10
Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther (2012) 1.10
Humanized Rag1-/- γc-/- mice support multilineage hematopoiesis and are susceptible to HIV-1 infection via systemic and vaginal routes. PLoS One (2011) 1.09
Evidence for X-chromosomal schizophrenia associated with microRNA alterations. PLoS One (2009) 1.08
Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol (2002) 1.07
In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice. J Immunol (2012) 1.07
Small nuclear RNAs encoded by Herpesvirus saimiri upregulate the expression of genes linked to T cell activation in virally transformed T cells. Curr Biol (2005) 1.07
Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol (2006) 1.07
HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther (2005) 1.05
Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Clin Cancer Res (2006) 1.04
RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci (2003) 1.03
A bias-reducing strategy in profiling small RNAs using Solexa. RNA (2011) 1.02
Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods (2009) 0.99
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther (2012) 0.98
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood (2007) 0.97
Biosensor-based small molecule fragment screening with biolayer interferometry. J Comput Aided Mol Des (2011) 0.96
A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells. Blood (2011) 0.96
Cre-mediated reversible immortalization of human renal proximal tubular epithelial cells. Oncogene (2004) 0.95
Phenotypic and functional characterization of HIV-1-specific CD4+CD8+ double-positive T cells in early and chronic HIV-1 infection. J Acquir Immune Defic Syndr (2009) 0.95
Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor. J Clin Pharmacol (2010) 0.93
Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease. World J Gastroenterol (2008) 0.93
Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. J Vis Exp (2011) 0.92
Human brain EEG indices of emotions: delineating responses to affective vocalizations by measuring frontal theta event-related synchronization. Neurosci Biobehav Rev (2011) 0.92
Treatment of human immunodeficiency virus-related lymphoma with haematopoietic stem cell transplantation. Blood Rev (2003) 0.92
Lentiviral transduction of Tar Decoy and CCR5 ribozyme into CD34+ progenitor cells and derivation of HIV-1 resistant T cells and macrophages. AIDS Res Ther (2004) 0.92
Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res (2007) 0.91
RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol Ther (2002) 0.90
Epo receptors are not detectable in primary human tumor tissue samples. PLoS One (2013) 0.90